In the last 12 months, insiders at Rallybio Corp ($RLYB) filed 33 transactions with the SEC: 0 open-market purchases totaling $0 and 1 sales totaling $3,992. Net insider sentiment: net selling.
Rallybio Corp operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Lieber Jonathan I (Chief Financial Officer) — 4 transactions totaling $3,992
- HUNT RONALD (Director) — 5 transactions totaling $6
- MACKAY MARTIN (Director) — 3 transactions totaling $4
- PARMAR KUSH (Director) — 2 transactions totaling $2
- Liu Hui (Director) — 3 transactions totaling $1
View all SEC Filings for Rallybio Corp (RLYB).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 23, 2026 | Lieber Jonathan I | Chief Financial Officer | S | Common Stock | 789 | $5.06 | 4,115.0000 | 45,058,591 | 16.09% | 0.00% |
| Feb. 18, 2026 | Lieber Jonathan I | Chief Financial Officer | A | Common Stock | 2500 | $0.00 | 4,904.0000 | 45,058,591 | 103.99% | 0.01% |
| Feb. 18, 2026 | MACKAY MARTIN | Director | A | Option (Right to Buy) | 18055 | $3.60 | 18,055.0000 | 45,058,591 | 9999.99% | 0.04% |
| Feb. 18, 2026 | HUNT RONALD | Director | A | Option (Right to Buy) | 14305 | $3.60 | 14,305.0000 | 45,058,591 | 9999.99% | 0.03% |
| May 13, 2025 | Hopfner Robert Lorne | Director | A | Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 43,544,824 | 9999.99% | 0.07% |
| May 13, 2025 | Soteropoulos Paula | Director | A | Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 43,544,824 | 9999.99% | 0.07% |
| May 13, 2025 | Liu Hui | Director | A | Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 43,544,824 | 9999.99% | 0.07% |
| May 13, 2025 | MACKAY MARTIN | Director | A | Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 43,544,824 | 9999.99% | 0.07% |
| May 13, 2025 | Boudreau Helen M | Director | A | Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 43,544,824 | 9999.99% | 0.07% |
| May 13, 2025 | Chung Wendy | Director | A | Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 43,544,824 | 9999.99% | 0.07% |
| May 13, 2025 | HUNT RONALD | Director | A | Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 43,544,824 | 9999.99% | 0.07% |
| May 13, 2025 | Nash Christine A | Director | A | Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 43,544,824 | 9999.99% | 0.07% |
| Feb. 14, 2025 | Uden Stephen | Chief Executive Officer | A | Option (Right to Buy) | 453700 | $0.00 | 453,700.0000 | 43,544,824 | 9999.99% | 1.04% |
| Feb. 14, 2025 | Ryder Steven | Chief Medical Officer | A | Option (Right to Buy) | 180000 | $0.00 | 180,000.0000 | 43,544,824 | 9999.99% | 0.41% |
| Feb. 14, 2025 | Lieber Jonathan I | Chief Financial Officer | A | Option (Right to Buy) | 180000 | $0.00 | 180,000.0000 | 43,544,824 | 9999.99% | 0.41% |
| Jan. 2, 2025 | HUNT RONALD | Director | A | Option (Right to Buy) | 73571 | $0.70 | 73,571.0000 | 43,544,824 | 9999.99% | 0.17% |
| Jan. 2, 2025 | Hopfner Robert Lorne | Director | A | Option (Right to Buy) | 73571 | $0.70 | 73,571.0000 | 43,544,824 | 9999.99% | 0.17% |
| Jan. 2, 2025 | Liu Hui | Director | A | Option (Right to Buy) | 67857 | $0.70 | 67,857.0000 | 43,544,824 | 9999.99% | 0.16% |
| Jan. 2, 2025 | MACKAY MARTIN | Director | A | Option (Right to Buy) | 92857 | $0.70 | 92,857.0000 | 43,544,824 | 9999.99% | 0.21% |
| May 15, 2024 | Soteropoulos Paula | Director | A | Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 40,447,388 | 9999.99% | 0.04% |
| May 15, 2024 | Nash Christine A | Director | A | Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 40,447,388 | 9999.99% | 0.04% |
| May 15, 2024 | Hopfner Robert Lorne | Director | A | Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 40,447,388 | 9999.99% | 0.04% |
| May 15, 2024 | Chung Wendy | Director | A | Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 40,447,388 | 9999.99% | 0.04% |
| May 15, 2024 | HUNT RONALD | Director | A | Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 40,447,388 | 9999.99% | 0.04% |
| May 15, 2024 | Liu Hui | Director | A | Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 40,447,388 | 9999.99% | 0.04% |
| May 15, 2024 | Boudreau Helen M | Director | A | Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 40,447,388 | 9999.99% | 0.04% |
| May 15, 2024 | PARMAR KUSH | Director | A | Option (Right to Buy) | 16500 | $0.00 | 16,500.0000 | 40,447,388 | 9999.99% | 0.04% |
| Feb. 15, 2024 | Uden Stephen | Chief Executive Officer | A | Option (Right to Buy) | 216000 | $0.00 | 216,000.0000 | 40,447,388 | 9999.99% | 0.53% |
| Feb. 15, 2024 | MACKAY MARTIN | Executive Chairman | A | Option (Right to Buy) | 216000 | $0.00 | 216,000.0000 | 40,447,388 | 9999.99% | 0.53% |
| Feb. 15, 2024 | Lieber Jonathan I | Chief Financial Officer | A | Option (Right to Buy) | 120000 | $0.00 | 120,000.0000 | 40,447,388 | 9999.99% | 0.30% |
| Feb. 15, 2024 | Ryder Steven | Chief Medical Officer | A | Option (Right to Buy) | 120000 | $0.00 | 120,000.0000 | 40,447,388 | 9999.99% | 0.30% |
| Jan. 2, 2024 | PARMAR KUSH | Director | A | Option (Right to Buy) | 27118 | $1.77 | 27,118.0000 | 40,447,388 | 9999.99% | 0.07% |
| Jan. 2, 2024 | HUNT RONALD | Director | A | Option (Right to Buy) | 29096 | $1.77 | 29,096.0000 | 40,447,388 | 9999.99% | 0.07% |